Abstract
Introduction
Ž . Familial combined hyperlipidemia FCH is a multiw x genic disorder with an estimated prevalence of 1% 1 . Patients with FCH are characterized by an overproduction w x of apolipoprotein B and very low density lipoproteins 2 in combination with a relative impairment of lipoprotein catabolism, resulting in a characteristic increase of inter-Ž . mediate density lipoprotein IDL or remnant particles w x 3,4 . LDL-cholesterol, an established independent risk factor for cardiovascular disease, is usually only moder- w x ately elevated in FCH 5 . The predisposition for cardiovascular disease in FCH is not restricted to patients with hypercholesterolemia alone, but is also clearly demonstrable in predominantly hypertriglyceridemic FCH patients w x 6 . Therefore, additional factors contributing to accelerated atherosclerosis in FCH remain to be elucidated.
Ž . Endothelium-derived nitric oxide NO plays an important protective role during the early phases of atherow x sclerosis by inhibiting leucocyte adhesion 7 . In the course of atherosclerotic disease progression, NO may play a beneficial role in haemodynamically mediated coronary w x ischaemia by causing coronary vasodilatation 8 
and in
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0008-6363r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved. acute coronary syndromes by modulating the coagulatory w x response 9 . Accordingly, it has been suggested that impaired NO activity may serve as an indicator of increased cardiovascular risk. In patients with elevated LDLcholesterol levels we and others have previously demonstrated a significantly impaired NO-dependent vasorelaxw x ation 10,11 . No such information exists on the effect of either VLDL-or IDL-cholesterol on NO-dependent vasodilatation in vivo. Given the variable expression of hyperlipidemic profiles in FCH, one could expect that this disorder allows further determination of the lipid fractions relevant for impaired NO-mediated vasodilatation.
The prime objective of the present study was to test whether NO-mediated vasodilatation is impaired in patients with FCH without clinical signs of macroangiopathy and, if so, whether this impairment is reversible after short-term lipid-lowering therapy andror co-infusion of the substrate for NO, L-arginine. Our second objective was to study the relationship between NO-mediated vasodilatation and the variably elevated levels of individual lipid fractions.
Methods

Subjects
Studies were performed in 12 male patients, mean age Ž . Ž . 40 2 years range 23-47 years , with familial combined Ž . hyperlipidemia, characterized by 1 hyperlipidemia, defined as cholesterol andror triglyceride plasma concentra-Ž . tions ) 6.5 and 2.0 mmolrl, respectively; 2 at least one first-degree relative with a different lipoprotein phenotype Ž . than the index patient; and 3 at least one first-degree relative with an elevated plasma concentration of apoB and w x a history of premature myocardial infarction 3,12 . None had clinical signs of atherosclerotic disease on physical examination and ECG. Six were smokers. Forearm volume Ž . Ž . averaged 1249 65 ml, and body mass index 25.9 1.0 . Control studies were performed in 12 healthy male sub-Ž . Ž . jects, mean age 33 3 years range 25-50 years . Six were Ž . smokers. Forearm volume averaged 1210 75 ml, and Ž . mean body mass index 24.9 0.9 .
Study design
First, forearm vascular function was studied in the absence of lipid-lowering therapy. For this purpose lipidlowering medication had been stopped 2 weeks prior to the investigation in nine cases, while three patients were not using maintenance lipid-lowering medication beforehand. Measurements were subsequently repeated after 4 weeks reinstitution of lipid-lowering therapy with simvastatin 40 mgrday. Out of twelve patients, six agreed to a third study, after cessation of lipid-lowering medication for 4 weeks. This final study was added to evaluate the reproducibility of the first measurement without medication and to evaluate a possible additional effect of 4 weeks compared to the two weeks period of cessation of medication. Control subjects were studied once. All studies were performed after an overnight fast of twelve hours. During this period all subjects also refrained from smoking and drinking alcohol or caffeine-containing beverages. The study protocol was approved by the Utrecht University Hospital Ethics Committee for study in human beings. Patients and control subjects gave written informed consent after explanation of the protocol. The investigation conforms with the principles outlined in the Declaration of Helsinki.
Infusion protocol
The protocol was performed as described previously w x Ž . 10 . In short, forearm blood flow FBF was measured in both arms at 15-second intervals by venous occlusion plethysmography with mercury-in-silastic strain-gauges using a microcomputer-based, R-wave triggered system for w x on-line, semi-continuous monitoring 10 . After cannulation of the brachial artery of the measurement arm sero-Ž . Ž tonin 5-HT, Sigma Chemical , sodium nitroprusside SNP, . Ž . Merck and L-arginine hydrochloride L-arg, Bufa were infused intra-arterially. The drugs were dissolved in 0.9% saline. All solutions were prepared aseptically from sterile stock solutions or ampoules on the day of the study and stored at 48C until use.
5-HT was administered in a cumulative dose infusion of 0.1, 0.3, and 1.0 ngrkgrmin. Each dose-step was infused for 5 minutes. 5-HT induced a rapid and transient vasodilatation, followed by a persistent vasodilatation. The latter is completely abolished by L-NMMA infusion, which indicates that NO is the sole agent responsible for its vasodilaw x tor effect 10,13 . Endothelium-independent vasodilatation was studied by infusing SNP in a cumulative dose of 1, 10, w x 30 and 100 ngrkgrmin 10 . Each dose-step was infused for 3 minutes. Calculations were based on measurements made during the final 1.5 min of each infusion step. Afterwards, the same infusions were repeated during co-inw x fusion of L-arginine in a dose of 0.2 mgrkgrmin 10 . . Rockville, MD . ApoB was measured using a nephelometric method with antiserum obtained from Behringwerke Žstandardization with International Federation of Clinical . Chemistry Reference Preparation SP3-07 .
Biochemical analysis
Calculations and statistics
During each infusion step the final six values of FBF from both measurement and control arm were used to calculate the mean FBF and the mean ratio of FBF be-Ž .w x tween measurement and control arm MrC ratio 15 .
Ž . From the MrC ratios curves were constructed Figs. 1-3 w x 15 . The area under the MrC curve was calculated using a Ž . curve-fitting computer program. The change in area un-Ž . der the MrC curve was used as an index of change in Ž . endothelium-dependent vasodilatation Fig. 4 . Correlations were tested with the Pearson-product moment test. 
Ž .
Results are expressed as means SE . Results of parameters with a skewed distribution are reported as medians w x range . Statistical analysis of differences in forearm blood flows and MrC ratios was performed using either repeated measures ANOVA when comparing data within the patient group, or ANOVA when comparing patients with controls. In case of an uneven distribution, ANOVA was performed after log-transformation of the data. If variance ratios reached statistical significance, differences between the means were analyzed with the Student-Newman-Keuls test for p -0.05.
Results
There were no significant differences between patient and control group in age, body mass index, smoking habit or forearm volume. Mean arterial pressure and basal fore-Ž . arm blood flow were not significantly different Table 1 The highest dosage of serotonin increased FBF in the Ž . Ž . control group from 2.9 0.3 to 6.5 0.6 mlr100 mlrmin Ž . p -0.05 compared to baseline . In the FCH patients, taking no lipid lowering medication, FBF increased from Ž . Ž . Six out of twelve patients consented to a third experi-Ž . ment after a second 4 week period of discontinuation of the medication. Plasma lipid and plethysmographic data were representative for the whole group, as were the changes induced by lipid-lowering therapy. Levels of total cholesterol, LDL-, IDL-and VLDL-cholesterol were significantly lowered during lipid-lowering therapy, and not Ž different between first and second off-therapy periods rew x w spective findings at baseline 6.8 5.6-7.9 , 2.65 1.34- 
sponse upon serotonin, whereas this effect disappeared Ž . after discontinuation of therapy Fig. 3 .
Finally, we evaluated correlations between lipid fractions and forearm vascular function in all 12 FCH patients. Endothelium-dependent vasomotion was expressed as area Ž . under the curve AUC of the ratio of forearm blood flow Ž . between measurement and control arm MrC ratio upon Ž . serotonin stimulation AUC . There was no correlaserotonin tion between plasma VLDL-or LDL-cholesterol at base-Ž line and endothelium-dependent vasodilatation r sy0.14 . and y0.16 respectively . Also, correlation testing between endothelium-dependent vasodilatation and IDL-cholesterol Ž level at baseline did not reach statistical significance r s . Ž . y0.56; p s 0.056 Fig. 4 . In contrast, the larger the reduction in IDL-cholesterol upon lipid-lowering therapy, the higher the increase in endothelium-dependent vasomo-Ž . Ž . tion r sy0.64; p -0.05 Fig. 4 . There were no significant correlations between change in endothelium-depen-Ž . dent vasomotion and changes in VLDL-r s 0.09; ns or Ž . LDL-cholesterol r sy0.17; ns . Endothelium-dependent vasodilatation was also not correlated to respectively HDL-cholesterol, age, blood pressure, baseline forearm Ž . blood flow or Lp a .
Discussion
Over the last years it has become clear that endothelial NO release is a first line defense mechanism against the w x development of atherosclerosis 16 . Major cardiovascular risk factors such as elevated LDL-cholesterol levels, diabetes and smoking have now been associated with imw x paired NO-dependent vasorelaxation in vivo 10, 11, 17, 18 . The present study expands our previous finding of impaired NO-mediated vasodilatation in patients with inw x creased LDL-cholesterol 10 to patients with combined hyperlipidemia, in whom LDL-cholesterol was not significantly elevated compared to controls. This impairment in NO-mediated vasodilatation ameliorated after short-term lipid-lowering therapy with simvastatin and recurred after cessation of therapy. The latter not only underscores the validity of the observation, but also demonstrates that modulation of NO activity by lipid lowering therapy is a rapid process. This is in accordance with recent data, describing amelioration of endothelial function upon 4-12 w x weeks of lipid-lowering therapy 10,19-21 and even instantaneous improvement after a single session of LDLw x apheresis 22 .
The spectrum of FCH comprises a wide array of lipid abnormalities. In the present study, this group was characterized by increased fasting IDL-levels and variably increased levels of LDL-andror VLDL-cholesterol. We found that the severity of impairment in NO-mediated vasodilatation varied individually, whereas no correlation could be demonstrated with either VLDL-, IDL-or LDLcholesterol level at baseline. However, the improvement in NO-mediated vasodilatation following lipid-lowering therapy correlated to the decrease in IDL-cholesterol plasma concentrations, not to changes in LDL-or VLDLcholesterol levels. An atherogenic potential of IDLcholesterol and remnant particles is supported by several lines of evidence. First, epidemiological studies have obw x served that both presence 23-25 as well as progression w x 26-28 of vascular disease can also be associated with increased IDL-cholesterol. In accordance recent data from the MARS study have demonstrated an association between progression of atherosclerosis and IDL-cholesterol, whereas LDL-and VLDL-cholesterol were not correlated w x 29 . Second, the smaller remnant particles are known to w x penetrate more easily into the arterial wall 30 and, due to the presence of apoE, bind to receptors on arterial-wall macrophages, which may promote formation of foam cells w x 31,32 . Third, triglyceride-rich particles may promote atherogenesis through the metabolic consequences of hypertriglyceridemia per se, such as low HDL levels and w x induction of a procoagulant state 33 . Finally, several studies have observed that postprandial triglyceride concentrations were highly predictive of coronary artery disw x ease 34 , whereas delayed remnant clearance is a hallmark w x of FCH 3 . Our present observation suggests that impaired NO activity may be an additional mechanism, which potentially contributes to the atherogenic potential of IDLcholesterol. We previously found that lowering LDLcholesterol concentrations in patients with familial hypercw x holesterolemia improved NO-mediated vasodilatation 10 . Thus, absence of a correlation with LDL-cholesterol in the present FCH patients does not necessarily preclude a role in endothelial dysfunction for LDL-cholesterol. Notably, in the present study mean LDL-cholesterol level in patients with FCH was not significantly elevated compared to controls.
From the present data it cannot be excluded that HMGCoA reductase inhibitors influence NO activity indepenw x dent of the lipid-lowering effects of these drugs 35 . For example, statin therapy has been associated with reduction of ex-vivo platelet aggregation and production of thromw x boxane B and A 36 , while atherosclerotic disease has 2 2 been associated with increased production of constrictor w x prostanoids 37 . Consequently, NO activity could be facilitated by decreased vasoconstrictor tone. However, the observation that lipid-lowering therapy with other comw x w x pounds, such as fibrates 38 and cholestyramine 39 , also has beneficial effects on endothelium-dependent vasodilatation suggests that lipid-lowering per se may be the main factor causing improved NO activity.
Decreased bio-availability of NO by increased LDLcholesterol may be the consequence of either decreased availability andror affinity of the substrate for NOS or a w x decreased availability of cofactors of NOS 40,41 , which w x can in part be restored by L-arginine infusion 10,42 . In the present study we extend this observation to combined hyperlipidemia, since infusion of L-arginine could ameliorate the impaired response in the present FCH patients. Further studies are required to determine whether other mechanisms contributing to impaired NO-mediated vasodiw x lation, such as tetrahydrobiopterin deficiency 42 , are different during respectively increased LDL-andror increased IDL-cholesterol levels.
The clinical relevance of the present observation is twofold: First, impaired NO activity during not significantly elevated LDL-cholesterol levels and the correlation of reduction in IDL-cholesterol with improvement in NO activity upon lipid-lowering therapy reinforces the potential relevance of IDL-cholesterol as a cardiovascular risk factor in FCH. Second, the observed rapid modulation of NO-mediated vasodilatation in forearm vessels by lowering cholesterol, which is correlated to reduction in IDLcholesterol, implies that this anti-atherogenic potential of the endothelium can be improved by short-term lipidlowering therapy. 
